Table 3.
First‐line treatments for HCC patients
| All stages | Early stages | Advanced stages | P | |
|---|---|---|---|---|
| (N = 8999) | (N = 6594) | (N = 2405) | ||
| TACE | 47.6% | 44.6% | 55.8% | <0.001 |
| Hepatectomy | 27.8% | 28.6% | 25.7% | 0.007 |
| RFA | 17.9% | 22.6% | 4.7% | <0.001 |
| TAE | 3.9% | 2.4% | 8.1% | <0.001 |
| Sorafenib | 1.6% | 0.5% | 4.6% | <0.001 |
| PEI | 1.0% | 1.3% | 0.1% | <0.001 |
| HAIC | 0.3% | 0.0% | 0.9% | <0.001 |
The differences in rates between early and advanced stages were assessed and P‐values were calculated using Fisher's exact test. HCC, hepatocellular carcinoma; TACE, transcatheter arterial chemoembolization; RFA, radiofrequency ablation; TAE, transcatheter arterial embolization; PEI, percutaneous ethanol injection; HAIC, hepatic arterial infusion chemotherapy.